Immuneering (IMRX) Return on Equity (2021 - 2026)

Immuneering's Return on Equity history runs 6 years deep, the most recent figure standing at 0.0% for Q1 2026.

• In Q1 2026, Return on Equity rose 1.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (up 1.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
• Return on Equity was 0.0% for Q1 2026 at Immuneering, down from 0.0% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q4 2025 to a low of 0.02% in Q2 2025.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.0% in 2023.
• The sharpest annual moves came in 2022 and 2025: Return on Equity slipped 1 bps in 2022, then gained 1 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then decreased by 29 bps to 0.01% in 2023, then tumbled by 120 bps to 0.01% in 2024, then soared by 80 bps to 0.0% in 2025, then slipped by 3 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.